AKT1 and cancer: The study fell short of combining HDAC and mTOR/Akt inhibitors in the long term to understand the mechanism of drug resistance development, but similar findings in other cancers point toward a general mechanism of overcoming drug resistance associated with the combination of HDACi and mTOR inhibitors (52).